Insmed Seeks To Block Tercica Growth Hormone In Orphan Exclusivity Fight
Executive Summary
A battle for orphan drug exclusivity may be at the heart of a dispute between Insmed and Tercica over the companies' pending NDAs for growth hormone treatments
You may also be interested in...
Insmed Growth Agent iPlex Joins Tercica’s Increlex With Orphan Exclusivity
Insmed is focusing on the dosing schedule of its growth hormone treatment iPlex to distinguish it from Tercica's competing product Increlex
Insmed Growth Agent iPlex Joins Tercica’s Increlex With Orphan Exclusivity
Insmed is focusing on the dosing schedule of its growth hormone treatment iPlex to distinguish it from Tercica's competing product Increlex
Former TKT CEO joins Epix
Michael Astrue takes over as interim CEO of Epix Pharmaceuticals following the resignation of Michael Webb, who will remain involved as a consultant to the company. Astrue, the former CEO of Transkaryotic Therapies, joined the board of Tercica in August (1"The Pink Sheet" Aug. 22, 2005, p. 9)...